Literature DB >> 22584220

Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.

Haoming Zhang1, Wei C Lau, Paul F Hollenberg.   

Abstract

We reported previously the formation of a glutathionyl conjugate of the active metabolite (AM) of clopidogrel and the covalent modification of a cysteinyl residue of human cytochrome P450 2B6 in a reconstituted system (Mol Pharmacol 80:839-847, 2011). In this work, we extended our studies of the metabolism of clopidogrel to human liver microsomes in the presence of four reductants, namely, GSH, l-Cys, N-acetyl-l-cysteine (NAC), and ascorbic acid. Our results demonstrated that formation of the AM was greatly affected by the reductant used and the relative amounts of the AM formed were increased in the following order: NAC (17%) < l-Cys (53%) < ascorbic acid (61%) < GSH (100%). AM-thiol conjugates were observed in the presence of NAC, l-Cys, and GSH. In the case of GSH, the formation of both the AM and the glutathionyl conjugate was dependent on the GSH concentrations, with similar K(m) values of ~0.5 mM, which indicates that formation of the thiol conjugates constitutes an integral part of the bioactivation processes for clopidogrel. It was observed that the AM was slowly converted to the thiol conjugate, with a half-life of ~10 h. Addition of dithiothreitol to the reaction mixture reversed the conversion, which resulted in a decrease in AM-thiol conjugate levels and a concomitant increase in AM levels, whereas addition of NAC led to the formation of AM-NAC and a concomitant decrease in AM-GSH levels. These results not only confirm that the AM is formed through oxidative opening of the thiolactone ring but also suggest the existence of an equilibrium between the AM, the thiol conjugates, and the reductants. These factors may affect the effective concentrations of the AM in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584220      PMCID: PMC3400843          DOI: 10.1124/mol.112.079061

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

1.  Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

Authors:  Jung-Won Suh; Bon-Kwon Koo; Shu-Ying Zhang; Kyung-Woo Park; Joo-Youn Cho; In-Jin Jang; Dong-Soon Lee; Dae-Won Sohn; Myoung-Mook Lee; Hyo-Soo Kim
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

2.  Measurement of thiol-disulfide interchange reactions and thiol pKa values.

Authors:  J Houk; R Singh; G M Whitesides
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

Review 3.  Glutathione.

Authors:  A Meister; M E Anderson
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

4.  The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

Authors:  Pierre Savi; Jean-Luc Zachayus; Nathalie Delesque-Touchard; Catherine Labouret; Caroline Hervé; Marie-Françoise Uzabiaga; Jean-Marie Pereillo; Jean-Michel Culouscou; Françoise Bono; Pascual Ferrara; Jean-Marc Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

5.  Structure and stereochemistry of the active metabolite of clopidogrel.

Authors:  Jean-Marie Pereillo; Mohamed Maftouh; Alain Andrieu; Marie-Francoise Uzabiaga; Olivier Fedeli; Pierre Savi; Marc Pascal; Jean-Marc Herbert; Jean-Pierre Maffrand; Claudine Picard
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

Review 6.  Aspirin resistance and atherothrombotic disease.

Authors:  Peter J Mason; Alice K Jacobs; Jane E Freedman
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

7.  Population, acid-base, and redox properties of N-acetylcysteine conformers.

Authors:  B Noszál; D Visky; M Kraszni
Journal:  J Med Chem       Date:  2000-06-01       Impact factor: 7.446

8.  The standard redox potential of cysteine-cystine from the thiol-disulphide exchange reaction with glutathione and lipoic acid.

Authors:  P C Jocelyn
Journal:  Eur J Biochem       Date:  1967-10

9.  Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

Authors:  Pierre Fontana; Annabelle Dupont; Sophie Gandrille; Christilla Bachelot-Loza; Jean-Luc Reny; Martine Aiach; Pascale Gaussem
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

10.  Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.

Authors:  P Savi; J M Herbert; A M Pflieger; F Dol; D Delebassee; J Combalbert; G Defreyn; J P Maffrand
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

View more
  7 in total

Review 1.  Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers.

Authors:  Muzamil Khawaja; Janki Thakker; Riyad Kherallah; Masafumi Kitakaze; Hani Jneid; Dominick J Angiolillo; Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-18       Impact factor: 3.727

2.  Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.

Authors:  Haoming Zhang; D Adam Lauver; Benedict R Lucchesi; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2013-01-24       Impact factor: 4.436

3.  In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.

Authors:  Mitsuhiro Nishihara; Hitomi Yamasaki; Richard Czerniak; Helen Jenkins
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.441

4.  Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel.

Authors:  Zhi-Xia Qiu; Wen-Chao Gao; Yu Dai; Su-Feng Zhou; Jie Zhao; Yang Lu; Xi-Jing Chen; Ning Li
Journal:  Front Pharmacol       Date:  2016-10-07       Impact factor: 5.810

5.  Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men.

Authors:  Hyang-Ki Choi; Jong-Lyul Ghim; Jihong Shon; Young-Kyung Choi; Jin Ah Jung
Journal:  Drug Des Devel Ther       Date:  2016-10-25       Impact factor: 4.162

Review 6.  Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges.

Authors:  Manish B Shah
Journal:  Biomolecules       Date:  2022-09-01

Review 7.  Monooxygenase- and Dioxygenase-Catalyzed Oxidative Dearomatization of Thiophenes by Sulfoxidation, cis-Dihydroxylation and Epoxidation.

Authors:  Derek R Boyd; Narain D Sharma; Paul J Stevenson; Patrick Hoering; Christopher C R Allen; Patrick M Dansette
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.